Literature DB >> 8389224

The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms.

Y Y van der Hoek1, M E Wittekoek, U Beisiegel, J J Kastelein, M L Koschinsky.   

Abstract

Elevated levels of plasma lipoprotein(a) [Lp(a)] have been correlated with the development of atherosclerosis in human populations. Apolipoprotein(a) [apo(a); the distinguishing protein component of Lp(a)] is characterized by multiple repeats of a sequence that closely resembles kringle IV of plasminogen. Variably-sized Lp(a) isoforms that are observed in the human population have been shown to occur as a result of differences in the numbers of the repeated kringle IV units in apo(a). Using PCR analysis of human liver mRNA, we have analyzed apo(a) from 10 unrelated individuals in order to determine the presence or absence of kringle IV repeat #1, and #30-#37. Based on the apo(a) cDNA sequence published for one individual, these kringles all differ to some degree in amino acid sequence from the major kringle IV repeat, which is present in a number of identically repeated copies. We found that sequences corresponding to apo(a) kringle IV repeat #1, and #30-#37 were present in all individuals studied. This suggests that the inverse relationship that has been observed between Lp(a) isoform size and plasma Lp(a) levels is mediated by different numbers of identical kringle IV repeats, by an as yet undetermined mechanism. During the course of this study, we identified a Met-->Thr polymorphism in the apo(a) kringle IV repeat #37. The calculated frequencies of the Met and Thr alleles were 0.58 and 0.42 respectively. We did not observe a correlation between the Met-->Thr substitution and either plasma Lp(a) levels, or apo(a) transcript size.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389224     DOI: 10.1093/hmg/2.4.361

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  38 in total

Review 1.  Lipoprotein(a) and coronary heart disease risk.

Authors:  S M Marcovina; R A Hegele; M L Koschinsky
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

Review 2.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

Review 3.  Lipoprotein (a) measurements for clinical application.

Authors:  Santica M Marcovina; John J Albers
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 4.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

5.  Convergent evolution of apolipoprotein(a) in primates and hedgehog.

Authors:  R M Lawn; K Schwartz; L Patthy
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans.

Authors:  V Mooser; D Scheer; S M Marcovina; J Wang; R Guerra; J Cohen; H H Hobbs
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

Review 7.  Screening for and management of elevated Lp(a).

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

8.  Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Lars Berglund
Journal:  Atherosclerosis       Date:  2014-05-10       Impact factor: 5.162

9.  Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay.

Authors:  R W Evans; S S Sankey; B A Hauth; K Sutton-Tyrrell; M I Kamboh; L H Kuller
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

10.  Enhanced macrophage uptake of lipoprotein(a) after Ca2+-induced aggregate-formation.

Authors:  S Tanaka; A Yashiro; H Tasaki; Y Nakashima
Journal:  Lipids       Date:  1998-04       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.